How to access Dupixent for atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis, or COPD with eosinophilic phenotype from the UAE: 2026 pathway via UAE dermatology, pulmonology, allergy, ENT, gastroenterology, and pharmacy supply | Reserve Meds
*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.
The United Arab Emirates operates one of the most mature multi-specialty service networks in the wider region for the type 2 inflammation conditions where Dupixent is the prescriber's first-line biologic. Cleveland Clinic Abu Dhabi (dermatology, pulmonology, allergy, ENT, gastroenterology, paediatrics), Sheikh Shakhbout Medical City (SSMC), Sheikh Khalifa Medical City (SKMC), Tawam Hospital, Burjeel Medical City, Mediclinic City Hospital, Mediclinic Parkview Hospital, American Hospital Dubai, NMC Specialty, the Aster Hospitals network, Saudi German Hospital Dubai, Dr Sulaiman Al Habib Dubai, Magrabi Dermatology, and Rashid Hospital Dubai all run programmes covering moderate-to-severe atopic dermatitis in adults and children, severe eosinophilic and oral-corticosteroid-dependent asthma in adults and children, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, and chronic obstructive pulmonary disease with an eosinophilic phenotype. Dupixent (dupilumab, Regeneron and Sanofi) is the fully human IgG4 monoclonal antibody that blocks the alpha subunit of the IL-4 receptor and thereby suppresses both IL-4 and IL-13 type 2 cytokine signalling. UAE EDE (Emirates Drug Establishment) has registered Dupixent for the long-established adult atopic dermatitis and adult asthma indications since 2018; the newer CRSwNP, EoE, prurigo nodularis, paediatric subsets, and COPD indications have registration status that varies by indication and continues to evolve. For a UAE-resident patient whose disease has plateaued on conventional therapy or who has failed a prior biologic, the operational question is no longer whether IL-4 and IL-13 receptor blockade is reachable in the country: it is whether Dupixent is the right fit for the patient's specific indication, how the prescription is dispensed in 2026, what insurance will cover, what the pre-treatment screening looks like, and how the family handles the every-2-week (or every-4-week, or weekly for EoE) subcutaneous routine.
This page explains how the pathway works in 2026 for a UAE-resident patient. Atopic dermatitis is the most common entry point into Dupixent therapy across the GCC, so the page leads with the atopic dermatitis pathway. A dedicated section covers the other five approved indications (asthma, CRSwNP, EoE, prurigo nodularis, COPD) with eligibility per indication. It is concierge documentation written for a family already in conversation with a treating specialist who wants the operational reality laid out plainly.
Why Dupixent, and why now
Dupixent is dupilumab, a fully human IgG4 monoclonal antibody developed jointly by Regeneron and Sanofi from Regeneron's VelocImmune fully human antibody platform. The molecule binds to the alpha subunit of the interleukin-4 receptor (IL-4Ra), the shared subunit of the type I and type II IL-4 receptors. By binding IL-4Ra, dupilumab blocks the downstream signalling of both IL-4 and IL-13, the two central cytokines of type 2 inflammation. Type 2 inflammation is the unifying mechanism across atopic dermatitis, eosinophilic asthma, CRSwNP, EoE, prurigo nodularis, and the eosinophilic phenotype of COPD. Suppressing the IL-4 and IL-13 signal reduces eosinophil recruitment to tissues, dampens IgE production by B cells, restores epithelial barrier function in skin and esophagus, reduces mucus production in airway epithelium, and breaks the chronic itch and inflammation cycle that defines these conditions.
FDA timeline: adult moderate-to-severe atopic dermatitis March 2017; adult and adolescent (12+) asthma October 2018; adolescent atopic dermatitis March 2019; CRSwNP June 2019; paediatric atopic dermatitis (6 to 11 years) May 2020; paediatric asthma (6 to 11 years) October 2021; atopic dermatitis (6 months to 5 years) June 2022; EoE adult and adolescent (12+) May 2022; prurigo nodularis September 2022; EoE paediatric (1 to 11 years, at least 15 kg) January 2024; COPD with eosinophilic phenotype September 2024; paediatric asthma (6 months to 5 years) April 2025. This indication and age breadth is unmatched in the type 2 inflammation biologic class and is the reason Dupixent often shows up as the first specialist-prescribed biologic for a UAE patient with overlapping atopic conditions (the atopic march: AD plus allergic asthma plus allergic rhinitis plus CRSwNP plus EoE in various combinations).
Reserve Meds does not promote one biologic over another. The page describes the Dupixent pathway because Dupixent is the drug the patient has asked about. The competing type 2 inflammation biologic landscape in 2026 includes omalizumab (Xolair, anti-IgE), mepolizumab (Nucala, anti-IL-5), reslizumab (Cinqair, anti-IL-5), benralizumab (Fasenra, anti-IL-5Ra), tezepelumab (Tezspire, anti-TSLP), and tralokinumab (Adbry, anti-IL-13 for adult AD). The JAK inhibitor class (abrocitinib, upadacitinib) is an alternative for moderate-to-severe atopic dermatitis with a different mechanism and a different safety profile (small-molecule oral therapy with a class black-box warning).
What Dupixent is, in plain language
Dupixent is a subcutaneous injection. It is not an infusion and does not require a hospital infusion suite. After an initial training session at the prescribing physician's clinic or with a Sanofi nurse educator, most adult patients self-administer at home using either the Dupixent pre-filled pen (auto-injector) or pre-filled syringe at 300 mg, 200 mg, or 100 mg per device. Caregivers administer for younger paediatric patients after similar training. The drug requires cold-chain storage at 2 to 8 degrees Celsius; the carton is stable at room temperature for up to 14 days unopened if needed for travel.
The dosing schedule varies by indication and by age. For adult atopic dermatitis: 600 mg loading dose (two 300 mg injections at separate sites at the same visit) at week 0, then 300 mg every 2 weeks. For adult asthma: 400 mg loading (two 200 mg) at week 0, then 200 mg every 2 weeks, with the 600 mg load and 300 mg every 2 weeks schedule reserved for OCS-dependent asthma or asthma with comorbid moderate-to-severe atopic dermatitis. For CRSwNP: 300 mg every 2 weeks. For EoE: 300 mg once weekly (distinct cadence). For prurigo nodularis: 600 mg loading, then 300 mg every 2 weeks. For COPD with eosinophilic phenotype: 300 mg every 2 weeks. Paediatric atopic dermatitis dosing is weight-tiered: 5 to less than 15 kg gets 200 mg every 4 weeks; 15 to less than 30 kg gets 300 mg every 4 weeks; 30 to less than 60 kg gets 400 mg load then 200 mg every 2 weeks; 60 kg and above gets the adult regimen. Paediatric asthma and paediatric EoE follow similar weight-tiered tables.
This is not a one-shot or short-course therapy. Dupixent is taken for as long as it controls the disease. Patients who achieve a meaningful response typically stay on Dupixent for years.
Eligibility at a UAE specialist clinic
For UAE-resident patients, the prescribing specialties apply FDA and EMA criteria with local insurance adaptation. Eligibility is indication-specific:
1. Atopic dermatitis. Dermatologist or paediatric dermatologist confirms moderate-to-severe disease by IGA, EASI, BSA, and DLQI (or POEM in younger patients). Documented inadequate response to topical prescription therapies (corticosteroids, calcineurin inhibitors) or contraindication to those. Age 6 months or older. 2. Asthma. Pulmonologist or allergist (paediatric pulmonologist for younger patients) confirms moderate-to-severe asthma by GINA Step 4 or 5 criteria. Eosinophilic phenotype confirmed by blood eosinophil count (typically at least 150 cells per microlitre, with stronger benefit signal at higher counts) or FeNO at least 25 ppb; OR oral-corticosteroid-dependent asthma documented by current or recent OCS exposure. Age 6 years or older (and now 6 months and older per the 2025 expansion). 3. CRSwNP. ENT (otolaryngologist) confirms bilateral nasal polyposis on endoscopy and / or sino-nasal CT. Documented inadequate response to intranasal corticosteroids plus either systemic corticosteroid courses or sino-nasal surgery. Adult only. 4. EoE. Gastroenterologist or paediatric gastroenterologist confirms by endoscopy with biopsy showing at least 15 eosinophils per high-power field after a trial of proton-pump inhibitor therapy. Age 1 year and older, weight at least 15 kg. 5. Prurigo nodularis. Dermatologist confirms multiple intensely pruritic nodules, chronic course of at least 6 weeks, alternative causes excluded. Adult only. 6. COPD with eosinophilic phenotype. Pulmonologist confirms COPD by post-bronchodilator spirometry, eosinophilic phenotype by blood eosinophil count at least 300 cells per microlitre, inadequately controlled despite optimised triple inhaled therapy. Adult only.
Shared baseline elements across all indications:
7. Treatment history. Failure of (or contraindication to) appropriate prior therapy for the indication. Insurers commonly require documented prior failure of indication-appropriate first-line therapies. 8. Baseline laboratory panel. CBC with eosinophil count (relevant for asthma and COPD eligibility, and as baseline because transient eosinophilia is common on therapy), comprehensive metabolic panel, baseline immunoglobulin profile including total IgE (informative not gating), pregnancy test for women of reproductive potential. 9. Helminth infection screen for patients with epidemiologic risk or symptoms. Treat any pre-existing helminth infection before initiation. 10. Active opportunistic infection or any serious active infection is a reason to defer initiation until resolved. 11. Vaccination status review. Live vaccines (varicella, MMR, yellow fever, oral polio, BCG) not recommended during Dupixent therapy. Catch-up live vaccinations before initiation where feasible. Inactivated vaccines (annual influenza, pneumococcal, COVID-19, meningococcal conjugate for Hajj or Umrah travel) are permitted and recommended. 12. Conjunctivitis history review for atopic dermatitis patients. Patients with a history of conjunctivitis or with active conjunctivitis at baseline have a higher likelihood of conjunctivitis on therapy. This is not a contraindication but informs counselling and ophthalmology co-management plan. 13. Pregnancy and lactation discussion for women of reproductive potential.
A UAE patient should arrive at the biologic conversation with the most recent specialist documentation for the indication: current severity scores (EASI / IGA / BSA / DLQI for AD; FEV1, FeNO, blood eosinophils, exacerbation history for asthma; nasal polyp score and CT for CRSwNP; endoscopy and biopsy reports for EoE; lesion count and itch NRS for prurigo nodularis; spirometry and blood eosinophils for COPD), complete treatment history, prior biologic trial documentation if any, helminth and TB screening history where indicated, vaccination record, and the insurance pre-authorisation paperwork.
The UAE prescribing and supply picture, plainly
UAE EDE (the federal-level drug regulator) registration status for Dupixent is verified at intake. Dupixent has been one of the more broadly registered type 2 inflammation biologics in the UAE since 2018 for the adult atopic dermatitis and adult asthma indications. CRSwNP, EoE, prurigo nodularis, paediatric subsets across age brackets, and COPD have registration status that varies and continues to evolve. Where in-country registration is complete for an indication and age subset, local commercial pharmacy supply applies. Where registration has not yet caught up with the most recent FDA or EMA label, a named-patient European or US import pathway covers the case. The pathway:
1. Prescribing physician: a board-certified UAE specialist in the indication-appropriate discipline. Dermatology or paediatric dermatology for atopic dermatitis and prurigo nodularis. Pulmonology, allergy, or paediatric pulmonology for asthma. Pulmonology for COPD. ENT for CRSwNP. Gastroenterology or paediatric gastroenterology for EoE. The major UAE prescribing centres include Cleveland Clinic Abu Dhabi, SSMC, SKMC, Tawam, Burjeel Medical City, Mediclinic City and Parkview, American Hospital Dubai, NMC Specialty, Aster, Saudi German Hospital Dubai, Dr Sulaiman Al Habib Dubai, Magrabi Dermatology, and Rashid Hospital Dubai. DHA-licensed and DoH-licensed prescribers handle Dubai and Abu Dhabi sides respectively. 2. Pharmacy dispensing: hospital outpatient pharmacy or licensed community pharmacy with cold-chain handling. Dupixent pre-filled pens and syringes require 2 to 8 degree Celsius transport and storage. Hospital pharmacies hand off with a validated cold-chain container. Most major UAE community pharmacies handle Dupixent dispensing routinely. 3. Insurance pre-authorisation: Daman, Thiqa for Emirati nationals, AXA, Bupa Global, MetLife, Oman Insurance, Cigna, and the other major UAE commercial insurers all process Dupixent pre-authorisation routinely for the adult atopic dermatitis and adult asthma indications. CRSwNP, EoE, prurigo nodularis, paediatric subsets, and COPD pre-authorisation patterns vary by payer and by indication recency. Documented severity, prior-therapy failure, and specialist sign-off are the common requirements. Step requirements (prior topical therapy, prior oral therapy, sometimes prior alternative biologic) are the common pre-authorisation friction point. 4. Self-injection training: typically a single supervised session at the prescribing physician's clinic or via a Sanofi nurse educator visit. Most adult patients are comfortable with self-injection after 1 to 2 sessions. Caregivers train for paediatric patients. Patients who prefer clinic-administered dispensing can request that pathway. 5. Ongoing monitoring: specialty-specific follow-up cadence (dermatology at week 4, 12, 16, then quarterly through year one for AD; pulmonology with parallel cadence for asthma; ENT with endoscopy at week 24 and annually for CRSwNP; GI with repeat endoscopy and biopsy at week 12 to 16 for EoE). Conjunctivitis surveillance at every visit for atopic dermatitis patients. Eosinophil count at baseline and periodically. Helminth surveillance for patients with epidemiologic exposure.
The 2026 pathway, step by step
Week 0 to 1: Reserve Meds builds the documentation pack with the treating specialist's office. We collect current severity scores, photographs of involved skin if applicable, endoscopy and biopsy reports if applicable, spirometry and eosinophil data if applicable, complete treatment history, prior biologic trial documentation if any, baseline screening labs, helminth screen where indicated, vaccination record, and insurance card details. The prescribing office submits insurance pre-authorisation.
Week 1 to 4: Insurance pre-authorisation review. Most UAE commercial insurers turn this around within 2 to 4 weeks for adult AD and adult asthma; CRSwNP, EoE, prurigo nodularis, paediatric subsets, and COPD pre-authorisation may take longer. Some payers require prior biologic trial-and-failure documentation before approving Dupixent; we surface this requirement early.
Week 4 to 6: First dispensing at the prescribing physician's clinic or partner pharmacy. The indication-specific loading dose and self-injection training session are completed. Patient (or caregiver) takes home the next dose pen or syringe for the next scheduled injection.
Week 4 onwards: Patient self-injects at home per the indication-specific schedule (every 2 weeks for adult AD, asthma, CRSwNP, prurigo nodularis, COPD; weekly for EoE; every 4 weeks for many paediatric subsets). Reserve Meds coordinates cold-chain delivery of the next month's supply.
Week 4 to 16: Loading-phase completion and early-response assessment. Specialty-specific follow-up visits at week 4, 12, and 16 to assess response.
Week 16 onwards: Response assessment. Patients who respond continue on maintenance dosing. Patients with partial response may extend the response window through week 24 before re-assessment. Patients with inadequate response may switch within or across biologic classes under specialist supervision.
Ongoing: Maintenance dosing for as long as Dupixent controls the disease. Quarterly follow-up at minimum during the first year; less frequent for stable responders thereafter.
Cost band and insurance positioning
US WAC list price for Dupixent in 2026 is approximately USD 3,800 to 4,300 per 300 mg pre-filled pen or syringe. For an every-2-week regimen (most adult indications), monthly cost at list is approximately USD 7,600 to 8,600 and annual cost at list approximately USD 91,000 to 103,000. The weekly EoE regimen carries a substantially higher annual list price (approximately USD 200,000 plus). The weight-tiered paediatric regimens with q4w dosing are correspondingly lower (approximately USD 45,000 to 55,000 annual at list).
At 2026 indicative cross rates, the AED-equivalent annual cost band for the every-2-week adult 300 mg regimen is approximately AED 330,000 to 380,000 at list price. Paediatric q4w regimens land lower (approximately AED 165,000 to 200,000 at list). The weekly EoE regimen lands materially higher. Insurance pre-authorisation reduces out-of-pocket exposure substantially for covered patients. UAE commercial covers commonly include Dupixent for the registered indications. Thiqa for Emirati nationals covers Dupixent for the registered indications within the standard pre-authorisation framework.
For Emirati nationals with Thiqa coverage, the financial pre-authorisation conversation needs to start before the first dispensing, not after. Daman and other commercial covers vary; the prescribing physician's office is the gating step.
What to expect on Dupixent, by indication
Atopic dermatitis: itch reduction often noticeable within the first 2 to 4 weeks. EASI-50 in roughly half of patients by week 4; EASI-75 in approximately 50 percent and IGA 0/1 in approximately 38 percent at week 16 in monotherapy pivotal trials; higher in combination with topical corticosteroids (EASI-75 in approximately 65 percent at week 52 in CHRONOS). Sleep quality and DLQI improvement usually parallel EASI improvement. Paediatric response broadly comparable.
Asthma: severe exacerbation rate reduction of approximately 47 percent (200 mg arm) and 46 percent (300 mg arm) at year one in QUEST. FEV1 improvement approximately 0.32 L versus 0.14 L on placebo. Benefit concentrated in the eosinophilic phenotype subgroup. OCS-dependent patients (VENTURE): median 70 percent OCS dose reduction; 48 percent achieve complete OCS discontinuation by week 24.
CRSwNP: nasal polyp score reduction by approximately 2 points at week 24 versus baseline. Nasal congestion score and Lund-Mackay CT score parallel. Time to first sino-nasal surgery substantially extended.
EoE: histologic remission (peak intraepithelial eosinophil count of 6 or fewer per HPF) at week 24 in approximately 60 percent on weekly dupilumab versus 5 percent on placebo. Dysphagia Symptom Questionnaire improvement of approximately 12 points versus 6 on placebo.
Prurigo nodularis: at least 4-point Worst Itch NRS reduction at week 24 in approximately 60 percent on dupilumab versus 18 percent on placebo. Skin lesion count reduction parallel.
COPD with eosinophilic phenotype: 30 percent annualised reduction in moderate or severe exacerbations on dupilumab in BOREAS and 34 percent in NOTUS.
The first 4 to 16 weeks are the highest-vigilance window for response assessment and for conjunctivitis surveillance (AD patients). Patients not responding by week 16 (or week 24 for slower-responding indications) are reassessed; the prescribing specialist may extend the response window, switch within or across the type 2 inflammation biologic class, or move to JAK inhibitor (for AD) or alternative therapy class as appropriate to the indication.
Other approved indications, eligibility summary
Most UAE Dupixent patients are entering therapy for atopic dermatitis. For patients in the UAE entering Dupixent for one of the other approved indications, the eligibility summary:
- Asthma (adult and paediatric 6 months and older): moderate-to-severe asthma with eosinophilic phenotype (blood eosinophils typically at least 150 cells per microlitre, with stronger signal at higher counts; or FeNO at least 25 ppb) or oral-corticosteroid-dependent asthma. Pulmonology or allergy prescribing. - CRSwNP (adult): bilateral nasal polyposis with documented inadequate response to intranasal corticosteroids plus either systemic corticosteroid courses or sino-nasal surgery. ENT prescribing. - EoE (adult and paediatric 1 year and older, at least 15 kg): endoscopy-and-biopsy confirmation of at least 15 eosinophils per HPF after a PPI trial. Weekly dosing cadence. Gastroenterology prescribing. - Prurigo nodularis (adult): multiple intensely pruritic nodules, chronic course at least 6 weeks, alternative causes excluded. Dermatology prescribing. - COPD with eosinophilic phenotype (adult): post-bronchodilator spirometric confirmation of COPD, blood eosinophils at least 300 cells per microlitre, inadequately controlled on optimised triple inhaled therapy. Pulmonology prescribing.
For patients with multiple comorbid type 2 inflammation conditions (the atopic march: AD plus allergic asthma plus allergic rhinitis plus CRSwNP plus EoE in various combinations), Dupixent may treat multiple comorbid conditions simultaneously. This is part of the clinical rationale for the drug in many GCC patients and is worth surfacing in the eligibility conversation.
What to monitor
The most clinically distinctive Dupixent monitoring item is conjunctivitis, especially for atopic dermatitis patients. Approximately 10 to 20 percent of AD patients develop conjunctivitis on Dupixent. The presentation is typically bilateral red eye, itch, tearing, and occasional photophobia. Most cases are mild to moderate and respond to lubricants, lid hygiene, and topical corticosteroid drops under ophthalmology supervision. Ophthalmology referral at first sign that does not resolve within 48 hours. Patients should not wait for the next scheduled dermatology visit to flag this. Patients with a history of conjunctivitis or with active conjunctivitis at baseline have an ophthalmology co-management plan in place from the start.
Eosinophil count at baseline and periodically. Transient eosinophilia is common on Dupixent (typically returns to baseline within 6 to 12 months) and is generally benign. Sustained eosinophilia with new respiratory symptoms or systemic features prompts evaluation for eosinophilic pneumonia or eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is rare but reported, particularly in asthma patients tapering off oral corticosteroids.
Injection-site reactions: typically mild redness, swelling, or pain at the injection site; usually transient. Site rotation reduces incidence.
Oral herpes (HSV reactivation) and other common adverse events: usually managed without therapy interruption.
Helminth surveillance for patients with epidemiologic exposure. IL-4 and IL-13 blockade may impair host response to helminths; treat any new infection promptly.
Hypersensitivity including rare anaphylaxis: stop therapy if it occurs.
Live vaccines should be avoided during therapy.
Long-term safety data is now 7-plus years post-marketing. The profile has remained reassuring: no opportunistic infection signal, no malignancy signal, no class black-box warning.
Religious, ethical, and family-logistics framing
Dupixent is a fully human IgG4 monoclonal antibody produced in mammalian cell culture (Chinese hamster ovary cell line). There is no donor element, no human or animal source material in the active ingredient, and no foreign genetic content delivered to the patient. The classical analogy to vaccines and other recombinant biologics holds in UAE Islamic medical ethics, where biologics produced in this manner are generally treated as permissive with the standard expectation that the family decides in consultation with the treating physician. Excipient sourcing varies by manufacturer batch; patients with specific halal-certification requirements should ask the dispensing pharmacy to confirm excipient sourcing for the current lot.
The self-injection element is the practical pressure point for some UAE families. Patients or family members who are uncomfortable with home injection can request clinic-administered dispensing, though this adds friction and additional clinic visits. Most UAE patients are comfortable with self-injection after the initial training; the injection is subcutaneous, the pen is straightforward to use, and the technique is well established. For paediatric patients, caregivers train; the transition to self-administration in adolescence is a milestone conversation.
The cold-chain storage requirement is operationally important in the UAE summer climate. Patient counselling on home refrigerator placement (not in the door, not adjacent to the freezer compartment), travel handling (insulated cold-chain bag with a cold pack), and the 14-day room-temperature allowance in the original unopened carton is part of standard patient education.
Severe atopic dermatitis in a child, severe asthma in a child, EoE in a child, and CRSwNP in an adult all carry meaningful family-burden and quality-of-life dimensions. The chronic-disease burden includes sleep disturbance (atopic dermatitis itch, asthma cough), school absenteeism (paediatric AD, asthma, EoE), work absenteeism (adult CRSwNP, severe AD), feeding difficulty (EoE), body-image concerns (visible AD lesions, prurigo nodularis), and depression burden in patients and parents. The clinical conversation appropriately addresses these dimensions and includes referral to behavioural health support where indicated. Dupilumab itself has no CNS or mood signal; the psychosocial burden is from the underlying chronic disease, and the response to treatment generally improves these dimensions in parallel with the skin, lung, or sinus response.
Ramadan considerations: the every-2-week or every-4-week subcutaneous regimen is unaffected by Ramadan fasting; the injection schedule fits around the fasting day. EoE patients on the weekly regimen plan injection timing around the meal schedule. Asthma exacerbation risk during Ramadan deserves explicit conversation for OCS-dependent and severe eosinophilic asthma patients.
Vaccination during therapy: live vaccines (varicella, MMR, yellow fever, oral polio, BCG) are not recommended during Dupixent. Inactivated vaccines (annual influenza, pneumococcal, COVID-19, meningococcal conjugate for Hajj or Umrah travel) are permitted and recommended.
When Dupixent is the wrong drug
For a UAE patient with the following clinical profiles, the operational pathway shifts:
- Acute asthma exacerbation, status asthmaticus, or acute bronchospasm: Dupixent has no role in acute care. Standard rescue therapy (short-acting beta-2 agonist, systemic corticosteroids, oxygen, hospital admission as indicated) applies. - Asthma without an eosinophilic phenotype and without OCS dependence: response benefit is concentrated in the type 2 inflammation phenotype. Patients with non-eosinophilic neutrophilic asthma may not benefit from Dupixent; tezepelumab (Tezspire) is the biologic positioned across asthma phenotypes for patients who do not fit the eosinophilic profile. - CRSwNP responding adequately to intranasal corticosteroids alone: Dupixent is for inadequate response to first-line therapy. - EoE responding adequately to PPI therapy or to dietary elimination: Dupixent is for inadequate response to those first-line approaches. - COPD without an eosinophilic phenotype: COPD label is specifically for the eosinophilic phenotype (typically blood eosinophils at least 300 cells per microlitre). Non-eosinophilic COPD does not benefit. - Active helminth infection: treat the helminth before initiation. - Hypersensitivity to dupilumab or excipients: contraindicated. Severe hypersensitivity including anaphylaxis is rare but reported. - Active serious infection: defer initiation until resolved. - Need for live vaccination in the near term: complete the live vaccination then initiate Dupixent with an appropriate interval. - Severe conjunctivitis history with poor ophthalmology support: not a contraindication but a friction point that warrants an ophthalmology co-management plan before initiation, particularly for atopic dermatitis patients. - Pregnancy: not contraindicated per se but limited human data; the decision is individualised with the treating specialist.
Alternative type 2 inflammation biologics in 2026: omalizumab (Xolair, anti-IgE), mepolizumab (Nucala, anti-IL-5), reslizumab (Cinqair, anti-IL-5), benralizumab (Fasenra, anti-IL-5Ra), tezepelumab (Tezspire, anti-TSLP), tralokinumab (Adbry, anti-IL-13 for adult AD), lebrikizumab (Ebglyss, anti-IL-13 for adult AD), nemolizumab (Nemluvio, anti-IL-31Ra for prurigo). JAK inhibitor alternatives for adult AD: abrocitinib (Cibinqo), upadacitinib (Rinvoq).
Reserve Meds does not promote one biologic over another, and does not push a default biologic class. If the conversation with the treating specialist points toward a different biologic, a JAK inhibitor, or continued conventional therapy, the operational pathway shifts accordingly.
What Reserve Meds does on this case
We are a US-based concierge coordinator. We are not the prescriber and not the dispensing pharmacy. On a UAE Dupixent case we build the documentation pack with the treating specialist office, confirm UAE EDE registration status per indication and per age subset and the appropriate dispensing pathway, run the insurance pre-authorisation conversation alongside the clinical conversation, coordinate the cold-chain supply logistics for ongoing maintenance dispensing, organise self-injection training and the baseline screening the prescribing office requires, set up the ophthalmology co-management plan for atopic dermatitis patients where indicated, and stay with the case through the first year of dosing with handoff to the local prescriber for ongoing surveillance. Clinical decisions remain with your treating specialist.
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating specialist.
Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-05-20.